The recent appointment of Robert F. Kennedy Jr. as Health Secretary by Donald Trump has led to significant stock market reactions, particularly affecting vaccine manufacturers such as Moderna, Pfizer, and GSK. Following the announcement, these companies experienced notable declines in their stock prices, with Moderna seeing a drop of approximately 10% and Pfizer and Novavax...
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here